Kornimate/medical-research-clean huggingface dataset:
oxidation-reduction homeostasis in cognitive impairment patients after stroke

Conditions: Oxidative-reduction Homeostasis; Post-stroke Cognitive Impairment

Summary: cognitive impairment after ischemic stroke can affect not only the social adaptation ability, but also affect the comprehensive rehabilitation of patients. the damage of cognitive impairment after ischemic stroke is not lower than the body function defect after stroke. many studies have shown that oxidative stress is one of the pathophysiological mechanisms of ischemic cerebrovascular disease. many studies have reported that the oxidative-reduction of cells plays an important role in the life activities of organisms, affecting the health, aging and death of the organism. in the recent years, some scholars have suggested that post-stroke cognitive impairment may be related to oxidative-reduction homeostasis of the body, but the relevant evidence is lacking and needs to be further explored. therefore, the purpose of this study is to explore the effect of oxidation-reduction homeostasis on cognitive impairment in patients with ischemic stroke, and provide a theoretical basis for the prevention and treatment of cognitive impairment after ischemic stroke.


Eligibility criteria:
inclusion criteria: * 40-80 years old; * ischemic stroke for the first time or previous stroke but with no serious sequelae (mrs is 0 -2 points); * time from onset to treatment ≤48 hours; * conscious awareness, and with no obvious aphasia and visual impairment; * signed informed consent by patient self or legally authorized representatives. exclusion criteria: * intracranial hemorrhage or suspected subarachnoid hemorrhage; * transient ischemic attack; * patients with severe mental disorders or language disorders; * patients can not cooperate with evaluators, such as mental illness or dementia; * pregnant women or suckers; * researchers consider patients inappropriate to participate in the registry.
hot flashes and omega 3

Conditions: Hot Flashes; Fatty Acids; Menopause

Summary: the main objective is to evaluate the effects of omega-3 fatty acids on hot flashes frequency.


Eligibility criteria:
inclusion criteria: * menopause or peri menopause * complaining of hot flashes * social security affiliation * informed consent form signed exclusion criteria: * primary pathology which can lead to hot flashes * allergy to omega-3 fatty acids * allergy to sea products * high consumption of fat fish or produced by the sea * iatrogenic hot flashes * actual omega-3 fatty acids consumption or in the 3 last months. * consumption of drug or other products for hot flashes in the last month * protected persons (l1121-5 to l1121-8 of french public health code)

Keywords: epa
positive appraisal improve trust between patients and therapists, and change treatment effects

Conditions: Trust; Low Back Pain

Summary: the trust between patients and medical providers is the cornerstone to obtain success treatment. to boost the trust can increase medical prescription compliance, enhance patient satisfaction, and improve the effectiveness of treatment. otherwise, mistrust between medical providers and patients will result in ineffective treatment and excessive defensive health care. this situation may cause medical dispute and medical resources wasting problems. most of treatment complete in a few times of admissions and interventions. so, how to improve the trust between patients and doctors quickly became a more knotty problem. several studies found that speech (including listening, showing compassion, and take longer to explain), reputation, clothing, offer a newer therapy were more important than age, title, and sex. however, past researches were restricted to an unclear causal relationship. that is they can't be determined whether good doctor-patient relationship and better trust conditions create a longer visit time, better satisfaction, and good reputation, or vice versa. they also unable to clarify whether the high degree of trust result in improved treatment effects, or good relationship result from good medical outcomes. investigators want to design a randomized control trial by giving patients recommendation and physical therapist introductions to enhance the trust of patients to therapists. and this study may verify whether enhance trust between therapists and patients will lead to changes in treatment effectiveness.


Eligibility criteria:
inclusion criteria: 1. first time visit to taoyuan general hospital rehabilitation ward at 2016/07/01\~2017/12/31 2. diagnosis with l spine spondylosis, l spine herniated inter-vertebral disc, or non-acute low back muscle strain 3. suitable for physical therapy with ( hot packing + interference current therapy + pelvic traction + therapeutic exercise ) 4. most pain score \>2 exclusion criteria: 1. poor of follow oral order, or patients who can't understand chinese, including patients with aphasia or dementia 2. patient who can not received 4 weeks of physical therapy 3. other cause of low back pain which can't treatment with physical therapy, including : (urinary tract stones, infection, rapid progression disease which need immediately operation)

Keywords: trust low back pain treatment outcome
reduced doses of antimony plus ranulocyte monocyte colony stimulating factor (gm-csf) for cutaneous leishmaniasis

Conditions: Cutaneous Leishmaniasis

Summary: the present study was designed as a randomized, single blind, placebo-controlled, study to evaluate the effect of 400 µg of recombinant human gm-csf applied intralesionally and associated with half of the total dose of antimony in a reduced time schedule (20mgsbv/kg/d for 10 days) as compared to the full dose of antimony (20mgsbv/kg/d for 20 days) to treat cutaneous leishmaniasis ulcers.

this is a randomized, single blind placebo-controlled study in which the groups were selected from the cases presenting to the health post. the inclusion criteria were: age between 15 and 50 years, of either sex, diagnosis of cutaneous leishmaniasis of less than 60 days. the diagnostic criteria were the presence of a typical single cutaneous ulcer, localized on lower limbs, and a positive delayed type hypersensitivity test (dth or montenegro skin test) to leishmania antigen.

Eligibility criteria:
inclusion criteria: * age between 15 and 50 years * either gender * diagnosis of cutaneous leishmaniasis * less than 60 days of disease exclusion criteria: * any history of prior anti-leishmania therapy * negative parasitology (aspirate/smear)or negative montenegro test * pregnancy * age below 15 and above 50 years * other associated acute or chronic illnesses * history of allergy to gm-csf and/or antimony * hiv, htlv-1 infections or diabetes * administrative reasons: * lack of ability or willingness to give informed consent (patient and/or parent / legal representative) * anticipated non-availability for study visits/procedures
pascoe-agil hom-injektopas in the treatment of rheumatic disorders

Conditions: Rheumatic Diseases; Arthralgia; Myalgias/Myopathy; Lumbago

Summary: the purpose of this observational study is to give an overview of the use of pascoe-agil hom-injektopas in a 2-4 week treatment of rheumatic disorders.

the purpose of this observational study is to give an overview of the use of pascoe-agil hom-injektopas in a 2-4 week treatment of rheumatic disorders of different aetiology and localisation, displaying a variety of symptoms. efficacy and tolerability of the drug will be assessed. special regard will be taken to the administration management in relation to the summary of product characteristics (smpc).

Eligibility criteria:
due to the design as an observational study no inclusion or exclusion criteria for therapy are named. the included patient group is described under "cohort / group". observational criteria (=inclusion criteria for documentation): * males and females * at least 18 years old * rheumatic disease with accompanying symptoms, e.g. arthralgia, myalgia, lumbago etc. exclusion criteria for documentation: * younger than 18 years * no rheumatic disease with accompanying symptoms, e.g. arthralgia, myalgia, lumbago etc. * no treatment with pascoe-agil hom-injektopas

Keywords: rheumatism arthralgia myalgia lumbago homoeopathy injection pascoe-agil hom injektopas efficacy tolerability acceptance safety
zinc status and growth in cystic fibrosis

Conditions: Cystic; Fibrosis

Summary: the purpose of this study is to improve the understanding of the relationship of zinc status and growth in infants and young children who were diagnosed with cystic fibrosis via newborn screening.

the objective of this study is to improve the understanding of the relationship of zinc (zn) status and growth in infant and young people with cystic fibrosis (pwcf). the investigators hypothesize that zn deficiency in infant and young pwcf is associated with poor growth. aim #2: to study the association between zn levels in red blood cells and nutritional status in pwcf at 3 months to 3 years of age and compare it to the association between serum zn and nutritional status in the same population. hypothesis: lower zn levels in red blood cells is associated with poorer nutritional status in infant and young pwcf and is a better measure of zn status compared to serum zn.

Eligibility criteria:
inclusion criteria: * pediatric patients ages 3 months to 3 years with cf identified via new born screening exclusion criteria: * history of meconium ileus * history of prematurity (born prior to completing 36 weeks 6 days gestation)

Keywords: zinc growth nutrition cystic fibrosis
the efficacy of capsaicin sensitivity testing in patients with irritable larynx syndrome

Conditions: Cough; Larynx

Summary: irritable larynx syndrome (ils) is a hyperkinetic laryngeal dysfunction that is characterized by a persistent cough, voice changes, or breathing difficulties, which are often triggered by an irritant. diagnosis of ils is difficult and typically made via a thorough review of the clinical history and, occasionally, the patient's reaction to an odor-provocation test. standard treatment for ils is behavioural therapy with a speech language pathologist (slp), which provides symptom improvement for most patients. however, currently, there are no objective measures of the upper airway hyper-responsiveness in this condition to assist in diagnosing and monitoring disease severity. since the cough is irritant-based, it is anticipated that patients with ils will have a hypersensitivity to the irritant capsaicin. capsaicin is the active component of chili peppers and is what makes them hot. the capsaicin cough challenge is a well recognized test that involves inhaling different concentrations of capsaicin solutions to determine a cough reflex sensitivity. the purpose of this research study is to confirm that ils patients have a hypersensitivity to capsaicin compared to healthy volunteers. if a hypersensitivity is observed in ils patients, the second objective of this study will be to see if behavioural therapy improves the cough reflex sensitivity in this patient population.

the proposed study has two purposes; the first is to utilize capsaicin cough challenge to demonstrate an increased efferent receptor sensitivity level in ils subjects as compared to a control group. the second is to determine if there is an objective change in capsaicin cough challenge results after behavioral therapy, and whether it correlates to the subjective improvement. self-reporting measures include two validated cough quality of life (qol) questionnaires collected at the same intervals as the capsaicin testing.

Eligibility criteria:
ils participants: inclusion criteria: * diagnosis of ils as per the st michael's voice clinic consultation * methacholine test performed * negative/borderline result for methacholine test and/or negative/incomplete response for asthma treatment * negative test result for gastroesophageal reflux or negative/incomplete response to reflux treatment * allergy test has been completed with negative result or does not account for all symptoms * agreed to behavioural therapy in smh voice disorders clinic exclusion criteria: * active smoker * active respiratory disease (e.g., copd, pulmonary fibrosis, lung malignancy.) * taking an ace inhibitor * pregnant and/or breastfeeding * impaired liver and/or renal function * neurological disorder * psychiatric condition (outside of depression or anxiety) healthy volunteers: exclusion criteria: * active smoker * active respiratory disease (e.g. copd, asthma) * ils diagnosis * chronic cough diagnosis * known hypersensitivity to capsaicin
3d evaluation of facial swelling post impacted lower third molars surgery: rct

Conditions: Swelling/ Edema; Impacted Third Molar Tooth

Summary: aim of the study is to evaluate the swelling following the osteotomy when performed with drilling bur versus piezo-electric instrument in the mandibular impacted third molar extraction, using a facial reconstruction software


Eligibility criteria:
inclusion criteria: * good general health conditions; * presence of bilateral and symmetrical impacted third molars (according to the classifications of winter and pell and gregory); exclusion criteria: * no clinical evidence of major facial asymmetry; * use of medication that would influence or alter wound healing; * temporomandibular joint disorder history; * smoking

Keywords: piezosurgery conventional osteotomy impacted lower third molar facial scan 3d rendering
comparison between intranasal vs intravenous dexmedetomidine for eeg sedation of children with behavior disorders.

Conditions: Sedation Complication

Summary: the aim of the project was to compare the efficacy and safety of intranasal (in) and intravenous (iv) dexmedetomidine (dex) in procedural sedation for electroencephalogram (eeg) in pediatric patients with behavioural disorders. single-centre comparative observational study in the tertiary care centre of padua, regarding all consecutive pediatric patients affected by behavioural disorders, who needed sedation for eeg recording. a group of children received iv administration of dex, the following year a second group of children received in administration of the same drug. target of sedation was level 2, according to the paediatric sedation state scale (psss).

objective: the aim of the project was to compare the efficacy and safety of intranasal (in) and intravenous (iv) dexmedetomidine (dex) in procedural sedation for electroencephalogram (eeg) in pediatric patients with behavioural disorders. methods: single-centre comparative observational study in the tertiary care centre of padua, regarding all consecutive patients \< 18 years old affected by behavioural disorders, who needed sedation for eeg recording. from 2018 to 2020 a group of children received iv administration of dex (iv dex), the following year a second group of children received in administration of the same drug (in dex). in both groups, target of sedation was level 2, according to the paediatric sedation state scale (psss). heart rate (hr), pulse oxygen saturation and blood pressure (bp) were registered. eeg recording quality and caregivers' satisfaction were collected.

Eligibility criteria:
inclusion criteria: * children affected by behavioural disorders, who need sedation to perform eeg * american society of anaesthesiologists (asa) status \< 3 * written informed consent by a parent or legal guardian. exclusion criteria: * previous hypersensitivity reaction or contraindications to administration of dex (cardiac failure, cardiac arrhythmias, long qt syndrome, bradycardia, hypotension, use of beta-blockers or digoxin, uncontrolled arterial hypertension, recent stroke or intracranial bleeding, moya-moya syndrome) * for in administration, children with runny nose/mild respiratory infection

Keywords: sedation dexmedetomidine safety
phase 1 clinical trial of pneumostem® treatment in premature infants with intraventricular hemorrhage

Conditions: Mesenchymal Stromal Cells

Summary: phase 1 clinical trial for the safety and dose determination of pneumostem (human umbilical cord blood derived mesenchymal stem cells) in the premature infants with intraventricular hemorrhage (ivh, grade 3-4)


Eligibility criteria:
inclusion criteria: * 23-34w * ivh grade 3-4, confirmed with brain ultrasonogram * within 7 days after ivh diagnosis exclusion criteria: * severe congenital anomaly * intrauterine intracranial bleeding * intracranial infection * severe congenital infection * active and uncontrolled infection, crp\>10mg/dl * platelet count \<50,000/ml * severe metabolic acidosis (ph\<7.1, be\<-20)

Keywords: intraventricular hemorrhage
intra-peritoneal local anaesthesia after cytoreductive surgery

Conditions: Pain

Summary: can perioperative administration of intra-peritoneal local anaesthetics further reduce postoperative pain, inflammation and outcome in patients undergoing major abdominal surgery (cytoreductive surgery) and managed with thoracic epidural analgesia? - multicenter study.

the aim of this study is to measure the efficacy of local anesthetics (la) administered into the intra-peritoneal cavity compared to placebo. our hypothesis is that the injection of local las intra-peritoneally would reduce post-operative pain and the inflammatory process caused by the massive release of cytokines during extensive cytoreductive surgery. the study is a controlled, parallel group, double blind, prospective, randomized and performed at sahlgrenska university hospital in goteborg, sweden . twenty ml of ropivacaine or saline would be injected every hour by an automatic pump via the intra-peritoneal catheter into the abdomen according to group randomization in order to double blind patients and all personnel involved in the study. the parameters that would be evaluated are inflammatory markers, postoperative morbidity, pain intensity, consumption of morphine, cognitive function and progression-free survival.

Eligibility criteria:
inclusion criteria: - patients with widespread malignant intra-abdominal ovary cancer stadium iii-iv and are operated by extensive resection of intra-abdominal viscera as well as the parietal peritoneum (cytoreductive surgery, crs) exclusion criteria: * body mass index \> 35 * american society of anesthesiologists classification \> 3 * renal dysfunction * allergic to acetylsalicylic acid * unwilling to provide informed consent

Keywords: analgesia local infiltration analgesia pain, relief pain, postoperative intra-peritoneal analgesia ropivacaine saline therapeutic uses analgesics, non-narcotic analgesics opioids morphine pain postoperative complications physiological effects of drugs anesthetics, local anesthetic cytoreductive surgery cancer
ketamine versus etomidate for rapid sequence intubation

Conditions: Airway Control; Anesthesia; Intubation; Complication

Summary: the purpose of this study is to compare the effectiveness and safety of ketamine and etomidate during rapid sequence intubation (rsi).

this study is a randomized controlled trial of etomidate versus ketamine during rapid sequence intubation (rsi). rsi refers to the process by which patients who require emergency airway management undergo sedation and paralysis prior to insertion of an endotracheal tube(airway tube). patients who require intubation will be randomized to have intubation performed with either ketamine or etomidate. all other care will be at the discretion of the treating physicians. the purpose of this study is to compare the efficacy and safety of ketamine and etomidate during rapid sequence intubation.

Eligibility criteria:
inclusion criteria: * 18 years of age * undergoing rapid sequence intubation (rsi) in the emergency department exclusion criteria: * known contraindication to ketamine or etomidate * patient has a condition in which an increase in heart rate or blood pressure would be hazardous, as judged by the treating physician * patient is known or suspected of having increased intracranial pressure, based on the history and physical examination performed by the treating physician. * females of child-bearing age, defined as 18-50 years, who do not have a documented pregnancy test in this institution confirming that they are not pregnant or who do not have a confirmed surgical procedure preventing pregnancy, i.e., tubal ligation, hysterectomy. the timing of the pregnancy test at which the investigative team will consider a subject to be non-pregnant is a documented negative test during current hospitalization or upon direct transfer from outside institution during current illness. * patient declines participation in the trial by wearing a bracelet marked "kve declined" * prisoner

Keywords: intubation airway emergent intubation rapid sequence intubation rapid sequence induction rsi ketamine etomidate sepsis sedative sedation
incidence of invasive pulmonary aspergillosis in ventilator-associated pneumonia

Conditions: Ventilator Associated Pneumonia; Pulmonary Aspergillosis Invasive

Summary: mechanically ventilated patients are at risk of developing ventilator-associated pneumonia (vap). invasive pulmonary aspergillosis (ipa), the diagnosis of which motivates the implementation of specific treatments, is one of the causes of vap. the hypothesis of the study is that the incidence of ipa is 12.4%. for each patient presenting with a suspicion of vap and requiring a bronchoalveolar lavage (bal), the diagnosis of api will be evaluated by biological examinations performed on blood and bal. medical and surgical history as well as clinical and biological data will be collected for 28 days or until discharge from the icu.


Eligibility criteria:
inclusion criteria: * adult patient (age ≥ 18 years), * on invasive ventilation for more than 48 hours, * suspected vap, defined by the appearance or worsening of a radiological pulmonary infiltrate, associated with 2 of the following clinical criteria: * fever ≥ 38° c or hypothermia ≤ 36.5° c * leukocytes \> 12x109 or \< 4x109/l * purulent tracheal secretions exclusion criteria: * neutropenic patients (neutrophils \< 0.5g/l), * previous diagnosis of ipa, * minor patients.

Keywords: pulmonary invasive aspergillosis ventilator-associated-pneumonia mechanical ventilation nosocomial infections
predictive factors for successful operative hysteroscopy using tissue removal device (truclear system) without anesthesia

Conditions: Uterine Polyp; Retained Products of Conception

Summary: background: small-diameter operative hysteroscopes may allow to perform operative hysteroscopy without general anesthesia in selected patients. one of these instruments is the tissue removal device (trd), which resects and removes intrauterine pathology such as endometrial polyps and retained products of conception (rpoc) with a diameter of ¬6 mm. objective: to assess the success rate and intraoperative pain of patients undergoing operative hysteroscopy without anesthesia with the trd (truclear elite mini-hysteroscope) for removal of endometrial polyps or rpoc. methods: prospective observational study. participation in the study was offered to patients diagnosed with uterine polyps or rpoc on office diagnostic hysteroscopy. the patients filled out a digital questionnaire before and after the operation. a successful procedure was defined as complete hysteroscopic removal of the uterine pathology using the truclear system. oral 400 mcg misoprostol 12 hours before the procedure was prescribed for cervical ripening.


Eligibility criteria:
inclusion criteria: * diagnosis of polyp or retained products of conception in diagnostic hysteroscopy. * medical need to remove the finding according to accepted criteria. * patient's consent to the removal of the finding in a procedure without anesthesia. * patient's consent to participate in the study. exclusion criteria: * any indication for performing the procedure under anesthesia in an operating room, such as: 1. medical background requiring operation in an operating room. 2. personal / mental background requiring procedure under general anesthesia. 3. cervical stenosis 4. previous failure to remove the finding in a procedure without anesthesia 5. lack of response to performing the operation without anesthesia * the lack of response to participate in the study * a known diagnosis of malignancy from a previous sample of the polyp or endometrium